Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Over time, consistent treatments help maintain steady energy, focus, and mood
NICE does not currently have guidance on either AOD 9604 or retatrutide, reflecting their unlicensed and investigational status within the UK healthcare system
Review source type and study model
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
US$ 28.47
US$ 20.35
US$ 21.16
US$ 22.95
US$ 27.30
US$ 27.93
US$ 27.62
US$ 23.04
